GlassScriptPhysician profile
Leon M Sujata
NPI 1154563724
$20,307.52
in general payments reported to CMS, 2019-2025
32 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $118 · 2021: $244 · 2022: $702 · 2023: $882 · 2024: $989 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,837 · Education: $40.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,836.69 |
| Education | $40.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $15,714.71 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $664.64 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $534.14 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Boston Scientific Corporation | $406.87 | 2019-2021 | |
| Travere Therapeutics, INC. | $363.23 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $339.60 | 2022-2025 | Terlivaz, Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $300.80 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $186.41 | 2024-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $169.53 | 2020-2025 | Jynarque |
| Bard Peripheral Vascular, INC. | $143.09 | 2019 | |
| Lilly USA, LLC | $128.80 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $127.58 | 2019-2025 | Vafseo |
| Vifor Pharma, INC. | $120.54 | 2022-2023 | Veltassa |
| Aurinia Pharma U.S., INC. | $118.27 | 2023-2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $112.63 | 2019-2025 | Velphoro, Velphoro, Korsuva |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.67 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $99.77 | 2025 | |
| Ani Pharmaceuticals, INC. | $99.14 | 2022-2024 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $86.61 | 2019-2025 | Rayaldee |
| Nxstage Medical, INC. | $70.31 | 2019 | |
| Alexion Pharmaceuticals, INC. | $57.57 | 2023-2025 | Ultomiris |
| Ardelyx, INC. | $51.94 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $44.57 | 2020-2023 | Injectafer |
| Genentech USA, INC. | $43.73 | 2019-2025 | Gazyva |
| Horizon Therapeutics Plc | $39.10 | 2022-2023 | Krystexxa |
| Ultragenyx Pharmaceutical INC. | $38.09 | 2022 | |
| Glaxosmithkline, LLC. | $36.86 | 2024-2025 | Benlysta, Arexvy, Shingrix |
| Scpharmaceuticals INC. | $28.68 | 2025 | |
| Novo Nordisk INC | $22.38 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.71 | 2024 | Gattex |
| Amag Pharmaceuticals, INC. | $19.35 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.20 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Sujata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.